2021

article thumbnail

The Importance of Regular Check-ups for Men

Drug Discovery Today

February 4th is World Cancer Day. As Covid continues to re-shape our lives it is important to keep awareness about men’s health high. Recent news about Greg Rutherford’s detection of a cyst is a reminder that it is important for men to get regular check-ups. Testicular cancer is one of the most common forms of cancer in males and it affects around 2,300 men in the UK each year.

201
201
article thumbnail

Generic Portfolio Management, Partnering with Brands, and Staying Competitive

Drug Patent Watch

This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry opportunities at the earliest stages Discovering opportunities that avoid litigation…. The post Generic Portfolio Management, Partnering with Brands, and Staying Competitive appeared first on DrugPatentWatch - Make Better Decisions.

144
144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Crisis Communications and FDA

Eye on FDA

In the face of a crisis situation, it is a given that the clarity and thoroughness of the communications response is key to resolving the issue and mitigating any reputational damage. Perhaps no other decision by the Food and Drug Administration has garnered as much controversy, as the recent one to authorize the accelerated approval a new treatment for Alzheimer’s.

FDA 105
article thumbnail

Why GoodRx—Not Amazon—May Be the True PBM Disrupter (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from August 2021. The generic prescription market is being disrupted—but not by the big, bad spaceman from Seattle. Instead, consider how GoodRx is affecting patients, payers, and PBMs.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics, LP today announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA of molnupiravir (EIDD-2801/MK-4482), an investigational oral antiviral agent.

Trials 69
article thumbnail

Potential new drug for incurable vascular dementia

Drug Discovery Today

A drug already used to treat high blood pressure could be re-purposed as the first treatment to tackle a type of vascular dementia caused by damaged and ‘leaky’ small blood vessels in the brain, according to research part-funded by the British Heart Foundation and published today in the Journal of Clinical Investigation.

Drugs 178

More Trending

article thumbnail

Upcoming workshop on generic portfolio management

Drug Patent Watch

I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans event on Portfolio Planning and Partnerships for Generics. The event…. The post Upcoming workshop on generic portfolio management appeared first on DrugPatentWatch - Make Better Decisions.

111
111
article thumbnail

Say ‘NO’ to bad contracts

Drug Patent Watch

Are you tired of having to naviagate complicated contracts to access the information you need? Let DrugPatentWatch free you from weeks of negotiating complex contracts and let you focus on…. The post Say ‘NO’ to bad contracts appeared first on DrugPatentWatch - Make Better Decisions.

109
109
article thumbnail

Workshop and lecture on generic portfolio management

Drug Patent Watch

I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans event on Portfolio Planning and Partnerships for Generics. The event…. The post Workshop and lecture on generic portfolio management appeared first on DrugPatentWatch - Make Better Decisions.

105
105
article thumbnail

Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review

Drug Patent Watch

This paper was originally published by Md. Imtiaz Hasan et al in Journal of Biosciences and Medicines under a Creative Commons Attribution 4.0 International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

DrugPatentWatch and Abbvie discuss Pharmaceutical Portfolio Management

Drug Patent Watch

Come join me and Wendi Lau from Abbvie as we participate in an interactive roundtable discussion on pharmaceutical portfolio management. We’ll be sharing our expertise and best practices for strategic…. The post DrugPatentWatch and Abbvie discuss Pharmaceutical Portfolio Management appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

New patent for Glaxosmithkline drug ANORO ELLIPTA

Drug Patent Watch

Annual Drug Patent Expirations for ANORO+ELLIPTA Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are fourteen patents…. The post New patent for Glaxosmithkline drug ANORO ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 104
article thumbnail

New patent expiration for Pfizer drug ZYVOX

Drug Patent Watch

Annual Drug Patent Expirations for ZYVOX Zyvox is a drug marketed by Pfizer and is included in three NDAs. It is available from four suppliers. There are two patents protecting…. The post New patent expiration for Pfizer drug ZYVOX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 104
article thumbnail

DrugPatentWatch featured in Inc Magazine

Drug Patent Watch

DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited our published interview where Mark Cuban Sounds off on Drug Prices.…. The post DrugPatentWatch featured in Inc Magazine appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

New patent for Amgen Inc drug CORLANOR

Drug Patent Watch

Annual Drug Patent Expirations for CORLANOR Corlanor is a drug marketed by Amgen Inc and is included in two NDAs. It is available from one supplier. There are eight patents…. The post New patent for Amgen Inc drug CORLANOR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

New patent for Teva Branded drug PROAIR RESPICLICK

Drug Patent Watch

Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

Drug Channels News Roundup, December 2021: CAR-T Profits, UM Boom, Health Plans vs. Experts, Confused Physicians, and Health Insurance Explained

Drug Channels

Happy New Year, everyone! We made it through a challenging 2021. Ring in 2022 with these noisemakers from the Drug Channels party bag: Hospitals earn incredible markups on CAR-T therapies Utilization management booms Health plans often ignore clinical guidelines Benefit designs flummox physicians Plus: an awesomely concise summary of U.S. health insurance.

article thumbnail

New patent for Allergan Holdings drug VIBERZI

Drug Patent Watch

Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

A Video History of Pharmacies and Prescription Prices: From Soda Fountains to GoodRx (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from August 2021. Charlotte Morabito at CNBC has put together “Why Pharmacies Overcharge,” an entertaining and provocative video on the pharmacy industry and its generic prescription pricing.

article thumbnail

Consolidation and Preferred Pharmacy Networks in 2022’s Medicare Part D Plans: Cigna, CVS Health, Humana, UnitedHealthcare, WellCare, and More

Drug Channels

Open enrollment is under way for the 2022 Medicare Part D plans. Our exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that preferred cost sharing pharmacy networks will maintain their dominance as an established component of Part D benefit design. For 2022: 98% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network. 66% of Medicare Advantage prescription drug (MA-PD) plans will have a preferred network.

article thumbnail

CVS, Walgreens, Walmart, and Supermarkets Keep Position in 2022 Part D Preferred Networks—With a Little Help from 340B

Drug Channels

In Consolidation and Preferred Pharmacy Networks in 2022’s Medicare Part D Plans , I highlighted how those networks have hijacked the world of stand-alone Medicare Part D prescription drug plans (PDP) and become a major presence in Medicare Advantage prescription drug (MA-PD) plans. Today, I examine the largest retail chains’ participation in the 21 major 2022 Part D preferred networks that the eight largest plan sponsors will offer.

article thumbnail

New patent for Alkermes Inc drug ARISTADA INITIO KIT

Drug Patent Watch

Annual Drug Patent Expirations for ARISTADA+INITIO+KIT Aristada Initio Kit is a drug marketed by Alkermes Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Alkermes Inc drug ARISTADA INITIO KIT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

New patent for Acadia Pharms drug NUPLAZID

Drug Patent Watch

Annual Drug Patent Expirations for NUPLAZID Nuplazid is a drug marketed by Acadia Pharms Inc and is included in two NDAs. It is available from one supplier. There are eighteen…. The post New patent for Acadia Pharms drug NUPLAZID appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

Pathway or Perish: The Two-Pronged Hurdle to Ensuring Access in Oncology

Drug Channels

Today’s guest post comes from Carolyn Zele, Senior Manager of Solution Enablement at MMIT. Carolyn describes how oncology pathways were developed to help standardize treatment and ensure quality care. She argues, however, that these pathways often shut manufacturers out of the market. Click here to learn more about MMIT's Pulse Analytics solution , which provides insight into payer- and pathway-driven barriers to access.

article thumbnail

New patent expiration for Glaxo Grp drug FLOVENT HFA

Drug Patent Watch

Annual Drug Patent Expirations for FLOVENT+HFA Flovent Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from four suppliers. There are…. The post New patent expiration for Glaxo Grp drug FLOVENT HFA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

New patent expiration for Novartis drug AMTURNIDE

Drug Patent Watch

Annual Drug Patent Expirations for AMTURNIDE Amturnide is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug. This drug has one…. The post New patent expiration for Novartis drug AMTURNIDE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

Conducting Patient Access in an Evolving Market

Drug Channels

Today’s guest post comes from Bill Dupere, Practice Lead and VP of Market Access Solutions and Eric Willis, VP of Operations Hub and Reimbursement Services at TrialCard. Bill and Eric discuss the complexities of digital patient support program technologies and introduce TrialCard’s integrated suite of solutions. To learn more, please contact Trialcard at sales@trialcard.com or visit them in booth #416 at the upcoming Asembia Specialty Pharmacy Summit from October 26 to 29, 2021.

article thumbnail

New patent for Tetraphase Pharms drug XERAVA

Drug Patent Watch

Annual Drug Patent Expirations for XERAVA Xerava is a drug marketed by Tetraphase Pharms and is included in one NDA. There are two patents protecting this drug. This drug has…. The post New patent for Tetraphase Pharms drug XERAVA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

New patent for Hq Spclt drug CALCIUM GLUCONATE IN SODIUM CHLORIDE

Drug Patent Watch

Annual Drug Patent Expirations for CALCIUM+GLUCONATE+IN+SODIUM+CHLORIDE Calcium Gluconate In Sodium Chloride is a drug marketed by Fresenius Kabi Usa and Hq Spclt Pharma and is included in two NDAs. It…. The post New patent for Hq Spclt drug CALCIUM GLUCONATE IN SODIUM CHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

How CVS Health Drives Cardinal Health’s Distribution Financials (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Outlook 2022. Hope you can join me! Click here to see the original post and comments from September 2021. Cardinal Health recently released the annual report for its 2021 fiscal year, which ended on June 30. See the links below. Today, I delve into the financials behind Cardinal’s relationship with its largest customer, CVS Health.

article thumbnail

How CVS Health Drives Cardinal Health’s Distribution Financials

Drug Channels

Cardinal Health recently released the annual report for its 2021 fiscal year, which ended on June 30. See the links below. Today, I delve into the financials behind Cardinal’s relationship with its largest customer, CVS Health. In Cardinal’s 2021 fiscal year, CVS purchased more than $42 billion in pharmaceuticals from the wholesaler—about double the figure from 10 years ago.

article thumbnail

New patent for Gilead Sciences drug EPCLUSA

Drug Patent Watch

Annual Drug Patent Expirations for EPCLUSA Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. It is available from one supplier. There are twenty-six…. The post New patent for Gilead Sciences drug EPCLUSA appeared first on DrugPatentWatch - Make Better Decisions.

Science 98
article thumbnail

New patent for Boehringer Ingelheim drug SYNJARDY

Drug Patent Watch

Annual Drug Patent Expirations for SYNJARDY Synjardy is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are six patents…. The post New patent for Boehringer Ingelheim drug SYNJARDY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

New patent for Boehringer Ingelheim drug SYNJARDY XR

Drug Patent Watch

Annual Drug Patent Expirations for SYNJARDY+XR Synjardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Boehringer Ingelheim drug SYNJARDY XR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98